BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.59bn
- SEK1.14bn
- SEK226.50m
Brief: BioInvent Q3 Sales SEK 12.8 Million
Brief: Bioinvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity
Brief: BioInvent Q2 Sales SEK 4.6 Million
Brief: Bioinvent To Present Pipeline Progress On Bi-1910 And Bt-001 At Esmo
Brief: Bioinvent Announces New Clinical Trial Collaboration
Brief: Bioinvent Gets Patent For Bi-1808 In China
Brief: BioInvent Q1 Sales SEK 5.9 Million
Brief: Bioinvent Announces Clinical Trial Collaboration, Supply Agreement With MSD
Brief: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206
Brief: BioInvent Q4 Sales SEK 15.3 Million
Brief: Bioinvent Regains Rights To Immuno-Oncology Targets From Exelixis
Brief: Bioinvent Says Is Well-Funded With SEK 1,358 Mln
Brief: BioInvent Presents Positive First Clinical Data On Anti-FcyRIIB Antibody BI-1607
Brief: Bioinvent Presents Data Providing Evidence Of The Potential Of Anti-Tnfr2 Antibody Bi-1910
Brief: BioInvent Q3 Adj. EPS at SEK -1.08
Brief: Bioinvent Announces Achievement In Collaboration With Exelixis, Gets USD 1 Mln Payment
Brief: Bioinvent: Phase 1 Study Part B, I.E. Bt-001 In Combination With Pembrolizumab To Start In H2
Brief: Bioinvent Reports Interim Safety Data, Early Signs Of Efficacy In Phase 1/2A Trial
Brief: BioInvent Announces Additional Efficacy Data From Phase 1/2 Trial With BI-1206 In Solid Tumors